TABLE 3
FROM:
Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents
A J Barrett and B N Savani
BACK TO ARTICLETable 3. Melphalan-based RIC regimens
| Ref | Year | Regimen | No. | Age range (median) | Disease | Donor type | GVHD prophy | aGVHD % (Grade) | cGVHD (%) | NRM (%) | Outcome (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 38 | 2006 | Flu 125–150 mg/m2
Mel 100–140 mg/m2 | 56 | 19–65 (51) | Hem malignancies | MRD | CSA MTX |
CSA 52 (I–IV) CSA+MTX 20 (I-IV) | CSA 64 CSA+MTX 26 | 16 (100 d) 24 (1 yr) | 1 yr OS-70 1 yr PFS-63 |
| 39 | 2006 | Flu 150 mg/m2
Mel 140 mg/m2 Campath | 41 | 37–64 (54) | CLL | MRD MUD Mismatch | CSA | 41 (I–IV) | 33 | 5 (100 d) 26 (2 yr) | 2 yr OS-51 2 yr PFS-45 |
| 30 a | 2005 | Flu 150 mg/m2
Mel 140 mg/m2 (FMC; n=80) OR Flu 90 mg/m2+BEAM (n=9)+Campath | 89 | 12–66 (51) | Hem malignancies | MUD Mismatch MRD | CSAMTX |
F-BEAM
14 (I–IV) FMC 52 (I–IV) | 62 | 17 (100 d) 33 (1 yr) | 3 yr OS-43 |
| 40 a | 2005 | Flu 125 mg/m2
Mel 140–180 mg/m2 | 26 | 26–59 (31) | HD | MRD MUD | Tacrolimus MTX | 38 (II–IV) 10 (III–IV) | 69 | 5 (100 d) 18 (18 mo) | 18 mo OS-73 18 mo PFS-37 |
| 41 | 2004 | Flu 90–180 mg/m2
Mel 70–160 mg/m2 ATG | 120 | 31–65 (52) | MM | MRD MUD Mismatch (n=4) | CSA MTX | 46 (II–IV) | 47 (Lim-25) (Ext-22) | 18 (1 yr) | 2 yr OS-59 2 yr EFS-39 |
| 42 | 2004 | Flu 150 mg/m2
Mel 140 mg/m2 Campath | 88 | 18–73 (48) | NHL | MRD MUD | CSA | 15 (II–IV) | 7 | 11–38 (3 yr) | 3 yr OS-55 (low grade NHL) |
| 43 | 2004 | Flu 100–150 mg/m2
Mel 140–180 mg/m2 | 62 | 22–75 (54) | AML MDS | MRD MUD Mismatch | Tacrolimus OR CSA+MTX |
MRD
20 (II–IV) 8 (III–IV) All 39 (II–IV) 19 (III–IV) | 39 | 26 (100 d) | 3 yr OS-34 3 yr PFS-32 |
| 44 | 2001 | Flu 125 mg/m2 OR (cladribine 12 mg/m2  5 days, n=8)Mel 140–180 mg/m2 | 86 | 22–70 (52) | Hem malignancies | MRD MUD Mismatch | Tacrolimus MTX | 49 (II–IV) | 68 | 37 (100 d) | 2 yr OS-28 2 yr DFS-23 |
| 45 | 2000 | Flu 150 mg/m2
Mel 140 mg/m2 Campath | 44 | 18–56 (41) | Hem malignancies | MRD MUD | CSAMTX | 10 (I–II) 0 (III–IV) | NA | 11 (1 yr) | 1 yr OS-73 |
Ref, reference number; AML, acute myeloid leukemia; ATG, antithymocyte globulin; CSA, cyclosporine; d, days; DFS, disease-free survival; Flu, fludarabine; MDS, myelodysplastic syndrome; Mel, melphalan; MMF, mycophenolate; MRD, matched related donor; MTX, methotraxate; MUD, matched unrelated donor; NA, not available; No, number of patients in the study; NRN, nonrelapse mortality; OS, overall survival; PFS, progression free survival; prophy, GVHD prophylaxis; TBI, total body irradiation; yr, year.
a Includes patients received other types of conditioning regimens.